Current challenges in Barrett's esophagus

Cleveland Clinic Journal of Medicine

Volumn 68, Issue 5, 2001, Pages 415-424

  Falk, Gary W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOPSY; CELL TRANSFORMATION; ESOPHAGUS TUMOR; GASTROESOPHAGEAL REFLUX; HUMAN; INTESTINE MUCOSA; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; TIME;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; INTESTINAL MUCOSA; TIME FACTORS;

EID: 0042833030     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.68.5.415     Document Type: Article

References (30)

1. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112:1448-1156.
2. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antiacid use may indicate significant illness. Arch Intern Med 1998; 158:2373-2376.
3. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92:118-124.
4. Sarr MG, Hamilton SR, Marrone GC, et al. Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux. Am J Surg 1985; 149:187-193.
5. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998; 93:1028-1032.
6. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99:918-922.
7. Johnson DA, Winters C, Spurling TJ, et al. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987; 91:23-27.
8. Grade A, Pulliam G, Johnson C, et al. Reduced chemoreceptor sensitivity in patients with Barrett's esophagus may be related to age and not to the presence of Barrett's epithelium. Am J Gastroenterol 1997; 92:2040-2043.
9. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103:1241-1245.
10. Eisen GM, Sandler RS, Murray S, et al. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997; 92:27-31.
11. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol 1997; 92:1293-1297.
12. Bremner CG, Lynch VP, Ellis FH. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 1970; 68:209-216.
13. Gillen P, Keeling P, Byrne PJ, et al. Experimental columnar metaplasia in the canine esophagus. Br J Surg 1988; 75:113-115.
14. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107:747-754.
15. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986; 315:362-371.
16. Fitzgerald RC, Triadafilopoulos G. Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis Sci 1998; 16:63-80.
17. Falk GW. Unresolved issues in Barrett's esophagus in the new millennium. Dig Dis 2000; 18:27-42.
18. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma. Cancer Causes Control 1996; 7:322-327.
19. Van Sandick JW, Lanschot JB, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43:216-222.
20. Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognized neoplastic lesions. Gastroenterology 1998; 94:81-90.
21. Falk GW, Chittajailu R, Goldblum JR, et al. Surveillance of Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology 1997; 112:1787-1797.
22. Haringsma J, Prawirodirdjo W, Tygat GN. Accuracy of fluorescence imaging of dysplasia in Barrett's esophagus [abstract]. Gastroenterology 1999; 116:A418.
23. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000; 46:574-577.
24. Ouatu-Laskar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117:327-335.
25. Williamson WA, Ellis FH, Gibb SP, et al. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg 1990; 49:537-542.
26. McDonald ML, Trastek VF, Allen MS, et al. Barrett's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996; 111:1135-1140.
27. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gasatrointest Endosc 1999; 49:1-7.
28. Gossner L, Stoite M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998; 114:448-435.
29. Morgan G, Vaino H. Barrett's oesophagus, oesophageal cancer and colon cancer: an explanation of the association and cancer chemopreventive potential of nonsteroidal anti-inflammatory drugs. Eur J Cancer Prevent 1998; 7:195-199.
30. Farrow DC, Vaughan TL, Hantsen PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomark Prevent 1998; 7:97-102.